Russell Investments國際已開發股票主動型ETF RINT 深 滬
等待開盤 11-04 09:30:00 美东时间
31.5345
-0.245
-0.77%
華盛通- 最 高31.69
- 今 開31.6192
- 成交量 1.54万股
- 最 低 31.51
- 昨 收 31.78
- 總市值 1.65亿
- 52周最高 35.9299
- 市盈率 靜 --
- 換手率 0.29%
- 52周最低 27.0934
- 委 比 0.00%
- 總股本 524.00万
- 歷史最高 35.9299
- 量 比 0.65
- 振 幅 0.57%
- 歷史最低 25.001
- 每 手 1
- 風險率 1.56%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Liquidia Corporation to Report Third Quarter 2026 Financial Results on November 10, 2026
Liquidia Corporation will report its third quarter 2026 financial results on November 10, 2026, and host a live webcast at 8:30 a.m. Eastern Time to discuss the results and provide a corporate update. The webcast will be available on Liquidia’s website and archived for one year. The company focuses on developing treatments for respiratory and vascular diseases using its proprietary PRINT® Technology, including YUTREPIA® for pulmonary arterial hyp...
11-03 13:30
Cimpress (CMPR) 2027财年第一季度业绩电话会议：EBITDA下滑之际维持业绩指引
Cimpress 2027 财年第一季度营收增长 8% 至 9.34 亿美元，而调整后 EBITDA 下降 9%。管理层维持了 2027 财年业绩指引，并加快了成本削减进程。
10-29 21:56
Liquidia Announces Global Settlement Resolving All Pending Litigation with United Therapeutics, Ensuring Continued Commercialization of YUTREPIA in PAH
Liquidia Corporation and United Therapeutics Corporation have reached a global settlement resolving all six ongoing lawsuits. YUTREPIA® for PAH patients remains available. Liquidia will pay $380.7 million in installments by 2027. Q3’26 YUTREPIA sales were $222.7 million, with $396.1 million in cash. Liquidia will continue advancing YUTREPIA and L606 programs.
10-13 21:44
Cimpress Completes Acquisition of SAXOPRINT and Viaprinto
The latest update is out from Cimpress ( ($CMPR) ). On July 2, 2026, Cimpress p...
07-03 05:04
